Recursion Pharmaceuticals, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Najat Khan
- Full Time Employees
- 600
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 41 South Rio Grande Street Salt Lake City UT United States 84101
- IPO Date
- Apr 16, 2021
- CIK
- 0001601830
- Website
- recursion.com
- Similar Companies
- Business
- Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company specializing in AI-driven drug discovery and development. The company offers an advanced drug discovery platform called the Recursion Operating System (Recursion OS), which integrates machine learning, automation, and large-scale biological and chemical datasets to accelerate the identification and development of novel drug candidates. Its product portfolio includes a pipeline of clinical and preclinical drug candidates targeting oncology and rare diseases, such as REC-617, an oral CDK7 inhibitor for advanced solid tumors, REC-1245, a potential first-in-class RBM39 degrader, REC-4881 for familial adenomatous polyposis, and REC-3964, a potential first-in-class Clostridioides difficile infection toxin B inhibitor. The company also develops biological maps including neuroscience phenomaps and owns proprietary datasets spanning phenomics, transcriptomics, proteomics, and patient data, supported by its automated wet lab platform. Recursion operates globally with key partnerships including Roche/Genentech, Sanofi, Bayer, and Merck KGaA. It was founded in 2013 and is headquartered in Salt Lake City, Utah. Recent major developments include acquiring full rights to the REV102 oral ENPP1 inhibitor program from Rallybio for treating hypophosphatasia, aiming to develop the first oral disease-modifying treatment for the rare genetic disorder. In 2024-2025, Recursion executed a significant business combination with Exscientia, enhancing its platform capabilities by integrating precision chemistry into drug design cycles. The company has streamlined its pipeline by discontinuing or pausing several late-stage drug programs as part of cost reduction and strategic reprioritization, focusing on six active development programs currently mostly in oncology and rare diseases. It secured milestone payments exceeding $500 million cumulatively from partnerships and maintains a strong cash position with a runway into late 2027. Its latest clinical milestones include promising safety and efficacy data from multiple programs and initiation of new clinical trials in solid tumors, lymphoma, and rare diseases, leveraging its AI-powered platform to innovate drug discovery and development processes. Recursion's industry focus lies in biotech and pharmaceutical sectors, targeting patients with aggressive cancers, rare diseases, and other conditions with high unmet medical needs through its proprietary tech-enabled drug discovery system. The company continues to develop its ecosystem of AI and wet lab capabilities to decode complex biology and accelerate the path to novel therapeutic solutions. Its strategic alliances and technology platform position it as a leading clinical-stage biotech entity advancing a data-driven approach to pharmaceutical innovation.
Company News
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
Recursion Appoints Fred Hassan as Chair of the Board
1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLC
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone